Our results were in accordance with previous studies in PCNSL, AITL, and PTCL (73, 74), indicating the predictive treatment effects and prognosis of MYC in EBV+ DLBCL patients. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.